Early immunotherapy for nerve damage linked to anti-Hu antibodies
Treatments studied
Part of Cancer clinical trials.
This trial tests whether a combination of three immune-suppressing drugs (IVIg, cyclophosphamide, and methylprednisolone) given early can improve balance and sensation in people with a rare nerve condition caused by anti-Hu antibodies. The goal is to stop or slow the nerve damage before it gets worse.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have been diagnosed with a sensory nerve problem (sensory neuronopathy) that affects your balance or walking
- Your blood or spinal fluid tests positive for anti-Hu antibodies
- Your nerve symptoms started less than 3 months ago
- You are able to visit the clinic and have a caregiver or support, but you can walk with some help (modified Rankin score 2 or 3)
- You have not had more than 2 courses of IVIg in the last 3 months or other immune treatments
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new cell-based treatment (called HY001N) for people with certain autoimmune neurological diseases that have not responded to standard treatments. The treatment aims to reset the immune system to reduce attacks and improve symptoms.
This trial studies whether IVIG (an immune therapy made from donated antibodies) can reduce pain from autoimmune small fiber neuropathy. You may be a candidate if your tests show certain autoantibodies (TS-HDS, FGFR3, or Plexin-D1) and your symptom scores are high enough.
This study tests a new treatment called CC-97540 (a type of CAR T-cell therapy) for people with neuromyelitis optica spectrum disorder (NMOSD), which is an autoimmune disease that affects the eyes and spinal cord. The goal is to see if this treatment is safe and tolerable.
This trial tests a new medicine (NouvSoma001) for people with neuromyelitis optica (NMOSD) who are having a flare-up. The goal is to see if the treatment is safe and if it helps reduce symptoms like pain and trouble moving.
This study looks at a treatment made from immune proteins (immunoglobulin M) to treat neuropathy caused by anti-MAG antibodies. It may help improve nerve symptoms in people with this specific type of nerve condition.
This study tests whether giving an infusion of antibodies (called IVIG) can reduce pain in people with nerve damage that causes burning or stabbing pain. If you have painful small fiber neuropathy or sensory neuronopathy, this treatment might help calm your nerves and ease your pain.
Hear when a new Paraneoplastic Sensory Neuronopathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.